Flashcards · Module 43
🦴 Second-Line Bone Anabolics & Advanced Osteoporosis
4 of 4 cards published · read by the site’s author on 22 November 2026
Teriparatide & Abaloparatide: Building bone from scratch
Needs clinical review
Anti-Resorptive vs. Anabolic Agents:
Bisphosphonates & Denosumab: Are "Anti-Resorptive" — they mainly inhibit osteoclastic bone resorption, with only later, secondary effects on bone formation.
Teriparatide (Forteo - recombinant human PTH 1-34) and Abaloparatide (Tymlos - PTHrP analog): Are ANABOLIC AGENTS — they stimulate osteoblasts to actively build new trabecular and cortical bone!
How Intermittent PTH Builds Bone:
Given intermittently (once-daily subcutaneous injections), teriparatide is anabolic, with effects most marked in trabecular bone.
Indications:
Very high fracture risk (UK guidance): a recent vertebral fracture (within 2 years), 2 or more vertebral fractures, or a T-score of −3.5 or lower
Second line when bisphosphonates are not tolerated
Dosing & Limits:
Daily subcutaneous injection (teriparatide 20 µg).
Duration: limited to 24 months, as a once-only course.
🚨 The Sequence Rule: When the anabolic course ends (teriparatide 24 months), start alendronate, zoledronate or denosumab without delay!
Sources checked (3) · 21 November 2026
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (2016)
- UK clinical guideline for the prevention and treatment of osteoporosis (2022)
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (2001)
Note: In a trial of one year of parathyroid hormone, the bone density gained was kept with alendronate but lost when no antiresorptive followed. (One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis (2005))
Romosozumab (Evenity): The dual-action sclerostin inhibitor
Needs clinical review
The Molecular Secret of Sclerostin:
Sclerostin is a regulatory factor in bone metabolism: blocking it increases bone formation.
How Romosozumab Works:
Romosozumab is a monoclonal antibody that binds and inhibits Sclerostin!
🟢 Stimulates bone formation.
🔴 Inhibits bone resorption.
Unlike most osteoporosis drugs, which are either anabolic or antiresorptive, it has a DUAL ACTION!
The Regimen:
Two subcutaneous injections once monthly for exactly 12 months.
Large, rapid rise in spine bone density (+11.3% in 1 year at 210 mg monthly, against 4.1% with alendronate and 7.1% with teriparatide, in a phase 2 trial).
🚨 The FDA Black-Box Cardiovascular Warning (THE BOARD TRAP!):
Romosozumab carries a black-box warning: it may increase the risk of myocardial infarction, stroke, and cardiovascular death!
Contraindication (US label): Do NOT start Romosozumab in a patient who has had a myocardial infarction or stroke within the past year!
Sources checked (4) · 21 November 2026
Note: In the US label, bone formation rises more than resorption falls. (DailyMed - EVENITY- romosozumab-aqqg injection, solution)
Note: UK guidance goes further: any history of myocardial infarction or stroke is a contraindication. (UK clinical guideline for the prevention and treatment of osteoporosis (2022))
Vertebroplasty vs. Kyphoplasty in Vertebral Compression Fractures
Needs clinical review
The Agony of a Collapsed Vertebra:
An 80-year-old with severe osteoporosis coughs and feels a sudden, excruciating, sharp thoracic back pain. X-ray confirms an acute L1 vertebral compression fracture.
The Two Minimally Invasive Procedures:
Vertebroplasty: Percutaneous injection of medical-grade bone cement into the fractured vertebra, under light sedation or general anaesthesia; the cement hardens into an internal cast.
Kyphoplasty: Similar, but an inflatable balloon is first expanded in the fractured vertebra, and then cement is injected.
The Great Clinical Controversy:
Sham-controlled trials (such as the landmark Buchbinder trials) showed that routine vertebroplasty had no significant benefit over a sham procedure for typical subacute fractures.
Does early treatment help? In the Cochrane review the effect did not differ by duration of pain (acute vs subacute).
Serious adverse events include osteomyelitis, cord compression, thecal sac injury and respiratory failure.
Sources checked (4) · 21 November 2026
- Percutaneous vertebroplasty for osteoporotic vertebral compression fracture (2018)
- A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures (2009)
- Percutaneous vertebroplasty for osteoporotic vertebral compression fracture (2018)
- UK clinical guideline for the prevention and treatment of osteoporosis (2022)
Vitamin D Dosing, Toxicity & Hypercalcemia: Avoiding annual mega-doses
Needs clinical review
The Essential Vitamin:
Vitamin D (25-OH-D) and calcium are key to skeletal health.
Diagnostic Targets:
Adequate: at least 20 ng/mL (50 nmol/L) meets the needs of 97.5% of people (IOM).
Higher is not better: higher levels were not consistently linked with more benefit, and some outcomes had risks at both low and high levels.
The Replenishment Protocol:
If deficient: a loading dose of 100,000 to 300,000 IU orally, in divided doses, followed by daily maintenance.
Daily Maintenance Dose: 800 up to 2,000 IU daily of vitamin D in osteoporosis, with calcium of at least 700 mg daily, preferably from the diet.
The Dangerous Mega-Dose Trap (The Board Question!):
Some clinicians gave patients a single, massive annual dose of 500,000 IU of Vitamin D once a year to improve compliance.
🚨 THE DISASTER: In a randomised trial, the annual mega-dose increased falls by 31% (in the first 3 months) and fractures by 26%!
Rule: routine large intermittent doses of vitamin D (e.g. 60,000 IU or more) are not advised: they were linked with more falls and fractures.
Sources checked (3) · 21 November 2026
- Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial (2010)
- The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know (2011)
- UK clinical guideline for the prevention and treatment of osteoporosis (2022)